# Pitolisant (BF2.649) in the Treatment of Excessive Daytime Sleepiness in Patients With Obstructive Sleep Apnoea Syndrome, Treated or Not by Nasal Continuous Positive Airway Pressure, But Still Complaining of Excessive Daytime Sleepiness

> **NCT02978651** · PHASE3 · WITHDRAWN · sponsor: **Bioprojet**

## Conditions studied

- Excessive Daytime Sleepiness
- Obstructive Sleep Apnea

## Interventions

- **DRUG:** Pitolisant (BF2.649)
- **DRUG:** Placebo Oral Tablet

## Key facts

- **NCT ID:** NCT02978651
- **Lead sponsor:** Bioprojet
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** —
- **Primary completion:** 2017-01
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Strategic decision of Sponsor
- **Last updated:** 2017-11-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02978651

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02978651, "Pitolisant (BF2.649) in the Treatment of Excessive Daytime Sleepiness in Patients With Obstructive Sleep Apnoea Syndrome, Treated or Not by Nasal Continuous Positive Airway Pressure, But Still Complaining of Excessive Daytime Sleepiness". Retrieved via AI Analytics 2026-07-28 from https://api.ai-analytics.org/clinical/NCT02978651. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*